291 related articles for article (PubMed ID: 28530521)
1. The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States.
Thayer S; Bell C; McDonald CM
J Manag Care Spec Pharm; 2017 Jun; 23(6):633-641. PubMed ID: 28530521
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
3. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage.
Klimchak AC; Szabo SM; Qian C; Popoff E; Iannaccone S; Gooch KL
J Manag Care Spec Pharm; 2021 Oct; 27(10):1426-1437. PubMed ID: 34595954
[No Abstract] [Full Text] [Related]
4. Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims.
Schrader R; Posner N; Dorling P; Senerchia C; Chen Y; Beaverson K; Seare J; Garnier N; Walker V; Alvir J; Mahn M; Merla V; Zhang Y; Landis C; Buikema AR
J Manag Care Spec Pharm; 2023 Sep; 29(9):1033-1044. PubMed ID: 37610111
[No Abstract] [Full Text] [Related]
5. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
6. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
[No Abstract] [Full Text] [Related]
8. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
[TBL] [Abstract][Full Text] [Related]
9. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
10. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.
Thornburg CD; Adamski K; Cook K; Vembusubramanian M; Sendhil SR; Hinds D; Chen E; Sammon J; Solari P; Garrison LP; Croteau SE
J Manag Care Spec Pharm; 2022 Apr; 28(4):449-460. PubMed ID: 34958235
[No Abstract] [Full Text] [Related]
11. Health care utilization and costs for children and adults with duchenne muscular dystrophy.
Teoh LJ; Geelhoed EA; Bayley K; Leonard H; Laing NG
Muscle Nerve; 2016 Jun; 53(6):877-84. PubMed ID: 26562484
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
Lu M; Oladapo A; Wu Y; Farahbakhshian S; Ewenstein B
J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
[No Abstract] [Full Text] [Related]
13. Association between health system specialty pharmacy use and health care costs among national sample of Medicare Advantage beneficiaries.
Hellems SS; Soni A; Fasching D; Smith BS; McManus DD
J Manag Care Spec Pharm; 2022 Feb; 28(2):244-254. PubMed ID: 35098745
[No Abstract] [Full Text] [Related]
14. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
Croteau SE; Cook K; Sheikh L; Chawla A; Sammon J; Solari P; Kim B; Hinds D; Thornburg CD
J Manag Care Spec Pharm; 2021 Mar; 27(3):316-326. PubMed ID: 33645244
[No Abstract] [Full Text] [Related]
15. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
16. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care.
Hong D; Avorn J; Wyss R; Kesselheim AS
JAMA Netw Open; 2024 Jan; 7(1):e2353094. PubMed ID: 38265797
[TBL] [Abstract][Full Text] [Related]
18. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
[TBL] [Abstract][Full Text] [Related]
19. Direct Costs of Opioid Abuse in an Insured Population in the United States.
White AG; Birnbaum HG; Mareva MN; Daher M; Vallow S; Schein J; Katz N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1188-1198. PubMed ID: 32996392
[TBL] [Abstract][Full Text] [Related]
20. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe.
Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():19-29. PubMed ID: 27038625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
